on behalf of the CREDO-Kyoto PCI/CABG registry cohort-2 investigators Background-There still remain safety concerns on surgical procedures after coronary drug-eluting stents (DES) implantation, and optimal management of perioperative antiplatelet therapy (APT) has not been yet established. Methods and Results-During 3-year follow-up of 12 207 patients (DESϭ6802 patients and bare-metal stent [BMS] onlyϭ5405 patients) who underwent coronary stent implantation in the CREDO-Kyoto registry cohort-2, surgical procedures were performed in 2398 patients (DESϭ1295 patients and BMSϭ1103 patients). Surgical procedures (early surgery in particular) were more frequently performed in the BMS group than in the DES group (4.4% versus 1.9% at 42-day and 23% versus 21% at 3-year, log-rank Pϭ0.0007). Cumulative incidences of death/myocardial infarction (MI)/stent thrombosis (ST) and bleeding at 30 days after surgery were low, without differences between BMS and DES (3.5% versus 2.9%, Pϭ0.4 and 3.2% versus 2.1%, Pϭ0.2, respectively). The adjusted risks of DES use relative to BMS use for death/MI/ST and bleeding were not significant (hazard ratio: 1.63, 95% confidence interval: 0.93 to 2.87, Pϭ0.09 and hazard ratio: 0.6, 95% confidence interval: 0.34 to 1.06, Pϭ0.08, respectively). The risks of perioperative single-and no-APT relative to dual-APT for both death/MI/ST and bleeding were not significant; single-APT as compared with dual-APT tended to be associated with lower risk for death/MI/ST (hazard ratio: 0.4, 95% confidence interval: 0.13 to 1.01, Pϭ0.053). Conclusions-Surgical procedures were commonly performed after coronary stent implantation, and the risk of ischemic and bleeding complications in surgical procedures was low. In patients selected to receive DES or BMS, there were no differences in outcomes. Perioperative administration of dual-APT was not associated with lower risk for ischemic events. (Circ Cardiovasc Interv. 2012;5:00-00.)
A report of 3 cases with perioperative stent thrombosis (ST) late (343 to 442 days) after drug-eluting stent (DES) implantation highlighted the increased risk of ST after surgical procedures. 1 Although most previous studies reported a relatively low rate of perioperative ST after surgical procedures in patients with prior DES implantation, [2] [3] [4] [5] [6] lingering safety concerns still remain on surgical procedures after DES implantation. Reflecting these safety concerns, a consensus statement from the American College of Cardiology and the American Heart Association recommended bare-metal stent (BMS) implantation or balloon angioplasty with provisional BMS implantation instead of DES implantation in patients undergoing percutaneous coronary intervention (PCI), who would be likely to require invasive or surgical procedures within 12 months, and recommended postponing elective surgery for at least 1 year in patients in whom a DES had been implanted 7 ; however, considering the scarcity of data supporting these recommendations, several issues need to be addressed regarding management of patients undergoing surgical procedures after coronary stent implantation. Safety of surgical procedures after DES implantation relative to those after BMS implantation has not been yet adequately evaluated. Furthermore, optimal management of perioperative antiplatelet therapy (APT), balancing ischemic and bleeding risk, has not been yet established. Therefore, we sought to investigate the incidence and predictors of the surgical procedures after coronary stent implantation and to evaluate ischemic and bleeding outcome after the surgical procedures, focusing on the impact of types of implanted stents (DES versus BMS), and status of perioperative APT (dual-, single-, and no-APT) in a large observational database in Japan.
WHAT IS KNOWN
• Surgical procedures after coronary drug-eluting stent implantation, early surgery in particular, carry significant risk for perioperative stent-related ischemic as well as bleeding complications.
WHAT THE STUDY ADDS
• Surgical procedures were commonly performed after coronary stent implantation in the real clinical practice in Japan (22% at 3 years).
• Incidences of ischemic and bleeding complications after surgical procedures were acceptably low, with no differences regardless of bare-metal stents and drug-eluting stents use.
• Perioperative administration of dual-antiplatelet therapy was not associated with lower risk for ischemic events.
Methods

Study Population
The Coronary REvascularization Demonstrating Outcome study in Kyoto (CREDO-Kyoto) PCI/coronary artery bypass grafting (CABG) registry cohort-2 is a physician-initiated non-companysponsored multicenter registry, enrolling consecutive patients undergoing first coronary revascularization, among 26 centers in Japan, between January 2005 and December 2007. The relevant review boards or ethics committees in all 26 participating centers (onlineonly Supplemental Appendix A) approved the research protocol. Because of retrospective enrollment, written informed consents from the patients were waived; however, we excluded those patients who refused participation in the study when contacted for follow-up. The study design and patient enrollment of the CREDO-Kyoto PCI/CABG registry cohort-2 were previously described in detail. 8 During the 3 years of enrollment period, 13 144 patients underwent PCI as the first coronary revascularization procedure. Excluding 57 patients (0.4%) who refused study participation and 880 patients (6.7%) without stent implantation, the study population for the current prespecified substudy of the CREDO-Kyoto PCI/CABG registry cohort-2 consisted of 12 207 patients who underwent coronary stent implantation. At least one DES was used in 6802 patients, while BMS was exclusively used in 5405 patients. During follow-up, non-CABG surgical procedures were performed in 2398 patients (DES: 1295 patients and BMS: 1103 patients), who constituted the study population for evaluating clinical outcome after surgery ( Figure 1 ).
Definitions
Surgical procedures during follow-up, excluding CABG, were captured as follow-up events after PCI. Surgical procedures were defined as the procedures performed under general, spinal, or local anesthesia. Percutaneous endovascular procedures were not regarded as surgical procedures, although gastrointestinal endoscopic therapeutic procedures were included in the surgical procedures. We excluded those surgical procedures related to the index PCI, such as vascular repair, and those related to mechanical complications of acute myocardial infarction at presentation. The type of anesthesia (general/spinal versus local anesthesia) was regarded as a surrogate for major versus minor surgery. The timing of the surgical procedures after stent implantation was categorized into the 2 prespecified subgroups (early surgery: within 42 days and late surgery: beyond 42 days after stent implantation), based on the previous reports suggesting increased risk for adverse events in patients undergoing surgical procedures within 6 to 8 weeks after BMS 9 -12 and DES 2,5,13 implantation.
The recommended APT regimen was aspirin (Ն81 mg daily) indefinitely and thienopyridine (200 mg ticlopidine or 75 mg clopidogrel daily) for at least 1 month after BMS implantation and for at least 3 months after DES implantation. The duration of dual-APT and management of perioperative APT was left to the discretion of each attending physician. Data on the status of APT was collected throughout the follow-up period. Persistent discontinuation was defined as withdrawal lasting at least 2 months. Status of perioperative APT was classified into the 3 groups (dual-, single-, and no-APT), according to the status on the day before the surgical procedures.
Clinical and procedural characteristics and medications were not evaluated at the time of the surgical procedures but were evaluated at the time of the index PCI procedures.
End Points
All the end points evaluated in this study were predefined. The primary outcome measures for ischemic and bleeding events were a composite of death, myocardial infarction (MI), or ST (definite/ probable) and moderate or severe bleeding by Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) classification, 14 respectively, which were assessed at 30 days after the surgical procedures. Individual components of the primary ischemic outcome measure were also evaluated. Definitions of other cardiovascular end points were previously reported. 8 definitions by experienced clinical research coordinators who belonged to the independent research organization (Research Institute for Production Development, Kyoto, Japan) (online-only Supplemental Appendix B). Baseline data forms were double-checked by a second clinical research coordinator in 1727 patients (13%). Follow-up data were obtained from hospital charts or by contacting patients or referring physicians. Clinical events such as death, MI, ST, and bleeding were adjudicated by the clinical event committee (online-only Supplemental Appendix C).
Median follow-up duration for surviving patients was 942 (interquartile range [IQR] : 676 to 1229) days. Complete 1-year follow-up information after the index stent implantation procedure was obtained in 11 770 patients (96.4%) out of 12 207 study patients. Complete 30-day follow-up information after the surgical procedure was available in 2302 patients (96.0%) out of 2398 eligible patients.
Statistical Analysis
Data are presented as values and percentages or mean valueϮstandard deviation or median and IQR. Categorical variables were compared with the 2 test or the Fisher exact test. Continuous variables were compared using the Student t test or Wilcoxon rank sum test, based on their distributions. Cumulative incidences of the surgical procedures after the index stent implantation and the clinical events after the surgical procedures were estimated by the Kaplan-Meier method, and differences were assessed with the log-rank test.
Clinical and procedural characteristics and baseline medications were compared between the 2 groups of patients with or without surgical procedures during follow-up (online only Supplemental Table I ). Multivariable logistic regression analysis was conducted to identify independent predictors for the occurrence of surgical procedures within 1 year after the index stent implantation. Those patients who did not complete 1-year follow-up without surgical procedures were excluded from the multivariable logistic regression analysis. Baseline characteristics of 901 patients excluded in the multivariable regression analysis were markedly different from those included in the analysis. Variables indicated in Table 1 were used as potential independent predictors. The continuous variables were dichotomized by clinically meaningful reference values or median values.
The effects of the types of implanted stents (DES versus BMS) and status of perioperative APT (dual-, single-, and no-APT) for the primary outcome measures were evaluated by multivariable Cox proportional hazard models. Patients with missing values were excluded from the multivariable analyses. Baseline characteristics of 256 patients excluded in the multivariable Cox proportional hazard regression analyses were not different from those included in the analysis. Potential independent risk-adjusting variables in the Cox models were indicated in Table 1 . Independent correlates for the primary outcome measures were identified by a backward elimination procedure. The final model incorporated the types of stents and status of perioperative APT, as well as types of anesthesia (general/ spinal versus local anesthesia) and timing of surgery (within 42 days versus beyond 42 days after stent implantation), together with those variables remaining after the backward procedure. Regarding status of perioperative APT, the effects of single-APT and no-APT relative to dual-APT were evaluated by using dummy variables. The effects of the types of stents and status of perioperative APT were expressed as hazard ratios (HR) and their 95% confidence intervals (CI).
All analyses were conducted by 2 physicians (Drs Tokushige and Shiomi) and a statistician (Morimoto) with the use of JMP 8.0 (SAS Institute Inc). All the statistical analyses were 2-tailed, and probability values Ͻ0.05 were considered statistically significant.
Results
Incidence and Predictors of Surgical Procedures
Patients with high-risk features such as old age, diabetes, renal failure, and acute myocardial infarction were commonly enrolled in the registry (Table 1 , and online-only Supplemental Table I ). During the 3-year follow-up after stent implantation, surgical procedures were performed commonly (22% at 3 years) (Figure 2A 1.9% at 42 days and 23% versus 21% at 3 years, log-rank Pϭ0.0007) ( Figure 2B ). Common surgical fields included vascular surgery, abdominal surgery, ophthalmic surgery, and gastrointestinal endoscopic procedures ( Table 2) .
As compared with patients without surgical procedures during follow-up, patients with surgical procedures were older and had more comorbidities (online-only Supplemental Table I ). Independent predictors for the occurrence of surgi- Continuous variables are shown as meanϮSD or median (interquartile range). There were missing values for BMI in 73 patients, for ejection fraction in 409 patients, for total stent length in 1 patient, for minimum stent size in 1 patient, for types of anesthesia in 49 patients, and for preoperative status of APT in 213 patients.
ACE-I indicates angiotensin converting enzyme inhibitor; APT, antiplatelet therapy; ARB, angiotensin receptor blocker; BMI, body mass index; BMS, bare-metal stents; COPD, chronic obstructive pulmonary disease; CTO, chronic total occlusion; DES, drug-eluting stents; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; H2-blocker, histamine type 2 receptor blocker; LAD, left anterior descending coronary artery; LMCA, left main coronary artery; PPI, proton pump inhibitor.
*Potential independent variables selected for the logistic regression model and the Cox proportional hazard models, and †potential independent variables selected for the Cox proportional hazard models only.
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cal procedures within the first year after coronary stent implantation, identified by multivariable logistic regression analysis, were advanced age, male gender, multivessel disease, shock at presentation, heart failure, atrial fibrillation, liver cirrhosis, malignancy, renal failure, insulin-treated diabetes, and anemia, although negative predictors were DESuse and acute myocardial infarction presentation (online-only Supplemental Table II) .
Clinical Outcome After Surgical Procedures
Cumulative incidences of the primary outcome measures for ischemic and bleeding events at 30 days after surgical procedures were low (death/MI/ST: 3.2% and GUSTO moderate/severe bleeding: 2.6%, respectively) ( Table 3) . Death was the dominant component of the primary ischemic outcome measure; however, the proportion of death related to postoperative ischemic complications was relatively small ( Table 4) . Incidences of MI and definite or probable ST at 30 days after surgical procedures were low (0.6% and 0.4%, respectively). Detailed information on 7 patients with angiographically documented ST was presented in online-only Supplemental Table III .
Minor surgery as compared with major surgery was associated with significantly lower risk for both ischemic and bleeding complications (Pϭ0.001 and Pϭ0.04, respectively) (online-only Supplemental Tables IV and V). Incidences of death/MI/ST and bleeding at 30 days after surgical procedures were both significantly higher in patients with early surgery than in patients with late surgery (Figure 3 , and online-only Supplemental Tables IV and V) 
Types of Implanted Stents and Clinical Outcome: BMS versus DES
Cumulative incidences of death/MI/ST and bleeding at 30 days after surgical procedures were not different between the BMS and DES groups ( Figure 5 ). The BMS group included more patients with acute myocardial infarction presentation, heart failure, peripheral vascular disease, malignancy, general/ spinal anesthesia, and early surgery, while the DES group included more patients with diabetes, prior MI, dialysis, anatomically complex disease, and perioperative dual-APT (Table 1) . After adjusting confounders, the risk of DES-use relative to BMS-use for ischemic and bleeding events remained insignificant (HR1.63, 95% CI: 0.93 to 2.87, Pϭ0.09, and HR: 0.6, 95% CI: 0.34 to 1.06, Pϭ0.08, respectively) (online-only Supplemental Tables IV and V). The higher risk for both ischemic and bleeding complications in patients with surgery within 42 days was consistently seen in both BMS and DES strata (online only Supplemental Figure I ). Incidence of definite or probable ST was not different between the BMS and DES groups (Table 3) . Regarding the causes of death, the proportion of death related to postoperative ischemic complications was also similar between the BMS and DES groups (Table 4) .
Status of Perioperative APT and Clinical Outcome
Cumulative incidence of persistent discontinuation of thienopyridine was significantly higher in patients treated with BMS than in patients with DES (PϽ0.0001) (online-only Supplemental Figure II Days patients, with median duration of discontinuation for 7 (IQR 6 to 12) days before surgery. Thienopyridines were reported to be resumed in 613 patients, with median interval of 4 (IQR 1 to 10) days. Cumulative incidences of death/MI/ST and bleeding at 30 days after surgical procedures were both significantly higher in patients with dual-APT than in patients with single-or no-APT ( Figure 6 ). Perioperative dual-APT was associated with a statistically insignificant trend for higher incidence of death/MI/ST in patients who underwent surgical procedures in the interval between 31 days and 1 year after an index PCI procedure (online-only Supplemental Figure III) . Patients in the dual-APT group had more comorbidities than patients in the single-or no-APT groups (online-only Supplemental Table VI) . After adjusting confounders, perioperative single-APT relative to dual-APT tended to be associated with lower risk for ischemic events and with similar risk for bleeding events (HR: 0.4, 95% CI: 0.13 to1.01, Pϭ0.053 and HR: 0.59, 95% CI: 0.22 to 1.42, Pϭ0.2, respectively), but the difference did not reach statistical significance. The risks of no-APT relative to dual-APT for both ischemic and bleeding events were not significant (HR: 0.64, 95% CI: 0.33 to 1.23, Pϭ0.2 and HR: 0.64, 95% CI: 0.33 to 1.27, Pϭ0.2, respectively) (online-only Supplemental Tables IV and V). The trend for higher risk for ischemic complications in the dual-APT group relative to single-APT group was consistently seen in both BMS and DES strata (Pϭ0.01 and Pϭ0.03, respectively) (online-only Supplemental Figure IV) . Incidence of definite or probable ST was not different across the 3 groups (single-APT: 0.2%, dual-APT: 0.5%, and no-APT: 0.4%, Pϭ0.8) (online-only Supplemental Table VII ).
Discussion
The main findings of this study are as follows: (1) plications after surgical procedures were acceptably low, with no differences, regardless of BMS and DES use; (3) perioperative administration of dual-APT was not associated with lower risk for ischemic events. Concordant with the recommendation by a consensus statement from the American College of Cardiology and the American Heart Association, 7 BMS instead of DES are predominantly used in the real clinical practice in patients who would be likely to require invasive or surgical procedures, which was clearly demonstrated by the higher incidence of early surgical procedure in the BMS group in the current analysis; however, in consistent with previous studies reporting 4% to 7% annual incidence of surgical procedures after stent implantation, 5, 6 ,15 the present study demonstrated that the need for surgical procedures often develop after a coronary stent has been implanted. Therefore, it is our contention that the recommendation to avoid the use of DES could hardly address the whole issues concerning surgical procedures after DES implantation. Furthermore, although surgical procedures after DES implantation, as compared with those after BMS implantation, are generally regarded as carrying higher risk for perioperative ischemic and bleeding complications, this notion has not been proven in clinical studies. Recently, a retrospective cohort study from Scotland analyzed 1953 patients with noncardiac surgical procedures after coronary stent implantation and found no differences between DES and BMS in the primary end point of inhospital mortality or ischemic cardiac events. 13 The current study, evaluating the largest-ever number of patients with surgical procedures after coronary stent implantation, consistently demonstrated that the incidence of the primary ischemic outcome measure at 30 days after surgery was not different between the BMS and DES groups. Acceptably low ischemic event rate in the DES group shown in the current study was consistent with our previous report, 5 although a rate of ST of 0.4% within 30 days appeared to be higher than the annual incidences of late and very late ST of 0.2 to 0.6% (0.02 to 0.05%/mo) reported previously. Furthermore, despite higher prevalence of perioperative dual-APT in patients receiving DES, 30-day bleeding outcome was also not different between the BMS and DES groups. According to these observations, choice of DES might be a reasonable option, even in patients who are likely to undergo surgical procedures, if risk of restenosis is expected to be very high.
Consistent with previous reports, 2,5,9 -13 surgical procedures performed early after coronary stent implantation were associated with significantly higher risk for both ischemic and bleeding complications than those performed late after coronary stent implantation. Therefore, it would be reasonable to postpone, whenever possible, surgical procedures at least a few months after coronary stent implantation. A consensus statement from the American College of Cardiology and the American Heart Association recommended postponing elective surgery for at least 1 year in patients in whom a DES has been implanted. 7 Although the optimal duration of the delay is not yet known, duration shorter than 1 year might be appropriate, considering the very low incidence of ischemic and bleeding events with surgical procedures beyond 42 days in the current study.
In the current analysis, perioperative administration of dual-APT as compared with single-or no-APT was not associated with lower risk for ischemic events. Although it seems to be paradoxical that the dual-APT as compared with single-APT tended to be associated with higher risk for ischemic events, bleeding could be a trigger for ischemic events. Perioperative administration of thienopyridines was reported to be associated with higher risk for bleeding, although discontinuation of both aspirin and thienopyridine was reported to be associated with higher risk for ST even beyond 1 year after DES implantation. 16 Therefore, it would be recommended to continue aspirin in most patients undergoing surgical procedures after coronary stent implantation except for those surgical procedures, such as intracranial surgery and spinal surgery, where serious clinical consequences are expected after bleeding.
Study Limitations
There are several important limitations in this study. First, we did not collect data on the clinical status at the time of surgical procedures and urgency of the procedures, which would be a critical determinant of clinical outcome after surgical procedures. Second, collection of follow-up data was conducted mainly based on hospital charts of the cardiology divisions. Underestimation of the incidence of surgical procedures is possible because the attending cardiologists might not have recognized all the surgical procedures conducted. Third, use of the GUSTO definition might be inappropriate for evaluating perioperative bleeding events. Fourth, ticlopidine instead of clopidogrel was used as the thienopyridine in most patients. Also, the dose of 200 mg of ticlopidine was much lower than the doses used outside Japan. Fifth, the baseline characteristics were markedly different between BMS and DES. Despite extensive statistical adjustment, the influence of unmeasured confounders and interactions of stent types with various clinical factors, including timing of surgery, and antiplatelet therapy made it very difficult to make comparison between BMS and DES. Furthermore, the comparisons between BMS and DES for ischemic and bleeding outcomes were obviously underpowered because of the small number of events, making it difficult to draw definitive conclusions. Finally, information on perioperative antiplatelet therapy might not be accurate because we did not systematically review the surgical hospital charts at the time of the surgical procedures. The surgeons might have had discontinued APT without notice to the attending cardiologists. Also, information regarding discontinuation of APT, obtained by contact with patients, was based on retrospective recall by the patients or relatives, suggesting a potential for recall bias. Furthermore, the risk of adverse cardiac events after surgical procedures are influenced by several factors other than the perioperative status of APT, including morbidities of patients, invasiveness of surgical procedures, timing of surgery after stent implantation, and different lengths of time of discontinuation of APT. In real clinical practice, perioperative management of APT would have had been modified according to the risk profile that a given patient had. This makes it very difficult to compare the risk of adverse events according to the perioperative status of APT.
Conclusions
Surgical procedures were commonly performed after coronary stent implantation, and the risk of ischemic and bleeding complications in surgical procedures after DES was low, without any difference from that after BMS. Perioperative administration of dual-APT was not associated with lower risk for ischemic events.
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